COVID-19診断法：世界市場の展望（2021年～2028年）

世界のCOVID-19診断法の市場規模は、2021年の671億1,996万米ドルから、2028年までに1,165億3,128万米ドルに達し、予測期間中に8.2％のCAGRで成長が予測されています。

当レポートでは、世界のCOVID-19診断法市場について調査分析し、市場動向分析、セグメント別・地域別の市場情報、企業プロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

• 促進要因
• 抑制要因
• 市場機会
• 脅威
• 製品分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

第5章 世界のCOVID-19診断法市場：テストタイプ別

• 分子（RT-PCR）テスト
• イムノアッセイテスト
• ポリメラーゼ連鎖反応（PCR）キット
• イムノクロマトグラフィー（LFIA）
• 抗体（血清学）検査
• 酵素結合免疫吸着測定法（ELISA）
• 抗原ベースのテスト

第6章 世界のCOVID-19診断法市場：ユーザー数別

• 多数
• 単独

第7章 世界のCOVID-19診断法市場：製品別

• アナライザー/機器
• 試薬・キット
• 消耗品

第8章 世界のCOVID-19診断法市場：設定別

• ラボベース
• ポイントオブケア（PoC）
• 非ポイントオブケア（非PoC）

第9章 世界のCOVID-19診断法市場：サンプルタイプ別

• 鼻咽頭・口腔咽頭スワブ
• 鼻スワブ
• 血

第10章 世界のCOVID-19診断法市場：エンドユーザー別

• プライベートラボ・コマーシャルラボ
• 医師のラボ/オフィス
• 病院・クリニック
• 公衆衛生研究所
• 研究所・診断センター
• 緊急医療クリニック
• 外来診療施設
• 調査

第11章 世界のCOVID-19診断法市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東・アフリカ

第12章 主な発展

• 契約・パートナーシップ・提携・共同事業
• 買収・合併
• 新製品の発売
• 拡張
• その他の重要な戦略

第13章 企業プロファイル

• Abbott Diagnostics
• Accelerate Diagnostics
• Ador Diagnostics
• Akkoni Biosystems
• Alveo Technologies
• Applied BioCode
• Aus Diagnostics
• BD Diagnostics
• Biocartis
• BioFire Diagnostics
• bioMerieux
• Bio-Rad Laboratories
• Bosch Healthcare Solutions GmbH
• Cepheid
• Co-Diagnostics
• Cue Health
• Curetis
• Diagenode Diagnostics
• Quest Diagnostics
• Trivitron Healthcare

List of Tables

• Table 1 Global COVID-19 Diagnostics Market Outlook, By Region (2020-2028) ($MN)
• Table 2 Global COVID-19 Diagnostics Market Outlook, By Test Type (2020-2028) ($MN)
• Table 3 Global COVID-19 Diagnostics Market Outlook, By Molecular (RT-PCR) Testing (2020-2028) ($MN)
• Table 4 Global COVID-19 Diagnostics Market Outlook, By Immunoassay Test (2020-2028) ($MN)
• Table 5 Global COVID-19 Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) Kits (2020-2028) ($MN)
• Table 6 Global COVID-19 Diagnostics Market Outlook, By Lateral Flow Immunoassay (LFIA) (2020-2028) ($MN)
• Table 7 Global COVID-19 Diagnostics Market Outlook, By Antibody (Serology) Testing (2020-2028) ($MN)
• Table 8 Global COVID-19 Diagnostics Market Outlook, By Enzyme-Linked Immunosorbent Assay (ELISA) (2020-2028) ($MN)
• Table 9 Global COVID-19 Diagnostics Market Outlook, By Antigen-Based Testing (2020-2028) ($MN)
• Table 10 Global COVID-19 Diagnostics Market Outlook, By Quantity of User (2020-2028) ($MN)
• Table 11 Global COVID-19 Diagnostics Market Outlook, By Multiple (2020-2028) ($MN)
• Table 12 Global COVID-19 Diagnostics Market Outlook, By Single (2020-2028) ($MN)
• Table 13 Global COVID-19 Diagnostics Market Outlook, By Product (2020-2028) ($MN)
• Table 14 Global COVID-19 Diagnostics Market Outlook, By Analyzers/Instruments (2020-2028) ($MN)
• Table 15 Global COVID-19 Diagnostics Market Outlook, By Reagents & Kits (2020-2028) ($MN)
• Table 16 Global COVID-19 Diagnostics Market Outlook, By Consumables (2020-2028) ($MN)
• Table 17 Global COVID-19 Diagnostics Market Outlook, By Setting (2020-2028) ($MN)
• Table 18 Global COVID-19 Diagnostics Market Outlook, By Lab-Based (2020-2028) ($MN)
• Table 19 Global COVID-19 Diagnostics Market Outlook, By Point-of-Care (PoC) (2020-2028) ($MN)
• Table 20 Global COVID-19 Diagnostics Market Outlook, By Non-Point-of-Care (Non-PoC) (2020-2028) ($MN)
• Table 21 Global COVID-19 Diagnostics Market Outlook, By Sample Type (2020-2028) ($MN)
• Table 22 Global COVID-19 Diagnostics Market Outlook, By Nasopharyngeal & Oropharyngeal Swab (2020-2028) ($MN)
• Table 23 Global COVID-19 Diagnostics Market Outlook, By Nasal Swab (2020-2028) ($MN)
• Table 24 Global COVID-19 Diagnostics Market Outlook, By Blood (2020-2028) ($MN)
• Table 25 Global COVID-19 Diagnostics Market Outlook, By End User (2020-2028) ($MN)
• Table 26 Global COVID-19 Diagnostics Market Outlook, By Private or Commercial Labs (2020-2028) ($MN)
• Table 27 Global COVID-19 Diagnostics Market Outlook, By Physician Labs/Offices (2020-2028) ($MN)
• Table 28 Global COVID-19 Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
• Table 29 Global COVID-19 Diagnostics Market Outlook, By Public Health Labs (2020-2028) ($MN)
• Table 30 Global COVID-19 Diagnostics Market Outlook, By Laboratories & Diagnostic Centers (2020-2028) ($MN)
• Table 31 Global COVID-19 Diagnostics Market Outlook, By Urgent Care Clinics (2020-2028) ($MN)
• Table 32 Global COVID-19 Diagnostics Market Outlook, By Ambulatory Care Settings (2020-2028) ($MN)
• Table 33 Global COVID-19 Diagnostics Market Outlook, By Research Institutes (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

According to Stratistics MRC, the Global COVID-19 Diagnostics Market is accounted for $67,119.96 million in 2021 and is expected to reach $116,531.28 million by 2028 growing at a CAGR of 8.2% during the forecast period. COVID-19 is an infectious disease caused due to Corona virus. Its symptoms include mild to moderate respiratory discomfort. While most may recover without any need for special treatment, the virus can cause major issues or serious illness and even death in older individuals and persons with underlying medical problems such as diabetes and cancers. As it has been the cause of numerous deaths, and infections in the past there is an urgent need for accurate diagnostic methods.

Market Dynamics:

Driver:

Rising prevalence of coronavirus disease

The sudden rise in the communicable coronavirus disease leading to a global pandemic has resulted in the escalating demand for COVID-19 diagnostic procedures and products. According to the Worldometer statistics, there has been a continuous rise in new daily cases across the globe. According to the World Health Organization (WHO), as of 18th May 2021, 163,312,429 people globally are affected with COVID-19. Such rapid daily rise in cases has surged the adoption of COVID-19 diagnostic tests so as to provide early treatment to patients. This is likely to increase the sales of reagents & kits used in the detection of the virus. Additionally, rising R&D activities are likely to drive market growth during the forecast period. Also, higher investments are being made by several companies to support the development of diagnostic solutions. For instance, in July 2020, the National Institutes of Health (NIH) invested USD 248.7 million in new technologies to address challenges associated with COVID-19 diagnostics (which detects SARS-CoV-2 coronavirus).

Restraint:

Stringent regulatory framework

Though the COVID-19 diagnostic market has tremendous potential and upcoming opportunities, there are some challenges that are likely to hinder the growth of the global market. Owing to the continuous rise in COVID-19 infections worldwide, the demand for better, safer, and faster detection kits to provide successful treatment to patients has created havoc in the diagnostics market. However, despite the dire need for these diagnostic tools, manufacturers have to pass through stringent regulatory restrictions to launch novel kits and maintain the supply chain. For instance, every country has its own regulatory authority implementing different regulations and guidelines for manufacturers. To ensure the safety of products, the U.S Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and other regulatory bodies have updated their guidelines. Moreover, increasing budgetary constraints are also likely to impact the market growth during the forecast period.

Opportunity:

Launch of innovative products

Protecting human lives is the most crucial element of the healthcare system during a pandemic situation. The need of the hour is to have accurate diagnostic procedures so as to receive early treatment. This has led pharmaceutical and medical device companies to invest in R&D to launch novel testing kits and assays. Large and small companies, as well as startups, are introducing new products for patients and healthcare personnel. For example, in May 2021, Cipla Limited, in partnership with Ubio Biotechnology Systems Pvt. Ltd announced the launch of the test kit ViraGen in India for corona diagnosis. This serology test is performed by collecting and analyzing saliva samples for detection of the coronavirus antigen.

Threat:

The stringent regulation of the framework

The restraining factor includes the stringent regulation of the framework and that mainly includes the development of the new test kits and which might be considered to be a limited covid 19 diagnostic market growth. In this situation, the dire need for the diagnostic tools appears to be stringent as it regulates launch the of novel kits and the maintenance of the supply chain management. This enables the safety of the products and it mainly includes the regulatory authority of implementation of the different regulations along with the guidelines for better manufacture.

The reagents & kits segment is expected to be the largest during the forecast period

The reagents & kits segment is expected to be the largest share during the forecast period due to the increasing demand for the products with respect to the increasing R&D in the companies coupled with the growing need for detection of the diseases. As these kits are one-time use, they need to be bought in bulk quantities and need to be supplied regularly.

Region with highest share:

Asia Pacific is projected to hold the largest share in the market due to increasing cases of coronavirus along with the presence of several industry players. APAC emerged as the largest Covid-19 diagnostics market and is likely to retain its position during the forecast year due to the widespread COVID infection in the population.

Region with highest CAGR:

North America is projected to have the highest CAGR in the market due to increasing virus testing rates, as this region is one of the most affected regions by the virus. For instance, according to the Worldometer statistics, the U.S. recorded more than 33 million cases as of May 2021 and conducted over 470 million tests.

Key players in the market:

Some of the key players profiled in the COVID-19 Diagnostics Market include Abbott Diagnostics, Accelerate Diagnostics, Ador Diagnostics, Akkoni Biosystems, Alveo Technologies, Applied BioCode, Aus Diagnostics, BD Diagnostics, Biocartis, BioFire Diagnostics, bioMerieux, Bio-Rad Laboratories, Bosch Healthcare Solutions GmbH, Cepheid, Co-Diagnostics, Cue Health, Curetis, Diagenode Diagnostics, Quest Diagnostics, and Trivitron Healthcare.

Key developments:

In July 2021: Abbott announced the launch of Panbio COVID-19 rapid antigen tests which will be available for self-testing to get easy and accurate results. The self-test features a minimally invasive nasal swab and delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology

In June 2021: Trivitron Healthcare, a medical technology company announced the launch of mobile laboratory for covid-19 testing to enable diagnostics in urban, rural areas and distant geographies to bring quality healthcare and diagnostic services close to the patients.

In May 2021: Quest Diagnostics Incorporated announced its collaboration with Ginkgo Bioworks to provide COVID-19 testing to K-12 schools across the U.S. Quest Diagnostics' expertise in COVID-19 testing can help kids and teachers learn more safely throughout Texas in person this school year.

Test Types Covered:

• Molecular (RT-PCR) Testing
• Immunoassay Test
• Polymerase Chain Reaction (PCR) Kits
• Lateral Flow Immunoassay (LFIA)
• Antibody (Serology) Testing
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Antigen-Based Testing

Quantity of Users Covered:

• Multiple
• Single

Products Covered:

• Analyzers/Instruments
• Reagents & Kits
• Consumables

Settings Covered:

• Lab-Based
• Point-of-Care (PoC)
• Non-Point-of-Care (Non-PoC)

Sample Types Covered:

• Nasopharyngeal & Oropharyngeal Swab
• Nasal Swab
• Blood

End Users Covered:

• Private or Commercial Labs
• Physician Labs/Offices
• Hospitals & Clinics
• Public Health Labs
• Laboratories & Diagnostic Centers
• Urgent Care Clinics
• Ambulatory Care Settings
• Research Institutes

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global COVID-19 Diagnostics Market, By Test Type

• 5.1 Introduction
• 5.2 Molecular (RT-PCR) Testing
• 5.3 Immunoassay Test
• 5.4 Polymerase Chain Reaction (PCR) Kits
• 5.5 Lateral Flow Immunoassay (LFIA)
• 5.6 Antibody (Serology) Testing
• 5.7 Enzyme-Linked Immunosorbent Assay (ELISA)
• 5.8 Antigen-Based Testing

6 Global COVID-19 Diagnostics Market, By Quantity of User

• 6.1 Introduction
• 6.2 Multiple
• 6.3 Single

7 Global COVID-19 Diagnostics Market, By Product

• 7.1 Introduction
• 7.2 Analyzers/Instruments
• 7.3 Reagents & Kits
• 7.4 Consumables

8 Global COVID-19 Diagnostics Market, By Setting

• 8.1 Introduction
• 8.2 Lab-Based
• 8.3 Point-of-Care (PoC)
• 8.4 Non-Point-of-Care (Non-PoC)

9 Global COVID-19 Diagnostics Market, By Sample Type

• 9.1 Introduction
• 9.2 Nasopharyngeal & Oropharyngeal Swab
• 9.3 Nasal Swab
• 9.4 Blood

10 Global COVID-19 Diagnostics Market, By End User

• 10.1 Introduction
• 10.2 Private or Commercial Labs
• 10.3 Physician Labs/Offices
• 10.4 Hospitals & Clinics
• 10.5 Public Health Labs
• 10.6 Laboratories & Diagnostic Centers
• 10.7 Urgent Care Clinics
• 10.8 Ambulatory Care Settings
• 10.9 Research Institutes

11 Global COVID-19 Diagnostics Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Abbott Diagnostics
• 13.2 Accelerate Diagnostics
• 13.3 Ador Diagnostics
• 13.4 Akkoni Biosystems
• 13.5 Alveo Technologies
• 13.6 Applied BioCode
• 13.7 Aus Diagnostics
• 13.8 BD Diagnostics
• 13.9 Biocartis
• 13.10 BioFire Diagnostics
• 13.11 bioMerieux
• 13.12 Bio-Rad Laboratories
• 13.13 Bosch Healthcare Solutions GmbH
• 13.14 Cepheid
• 13.15 Co-Diagnostics
• 13.16 Cue Health
• 13.17 Curetis
• 13.18 Diagenode Diagnostics
• 13.19 Quest Diagnostics
• 13.20 Trivitron Healthcare